Literature DB >> 19847907

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hans-Peter Hartung, Orhan Aktas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19847907     DOI: 10.1002/ana.21880

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  7 in total

1.  Intrathecal methotrexate treatment in multiple sclerosis.

Authors:  Saud A Sadiq; Elena V Simon; Lauren M Puccio
Journal:  J Neurol       Date:  2010-06-10       Impact factor: 4.849

Review 2.  [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].

Authors:  O Aktas; J Ingwersen; B Kieseier; P Küry; R Hohlfeld; H-P Hartung
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

3.  Heterogeneity versus homogeneity of multiple sclerosis.

Authors:  Fumitaka Sato; Nicholas E Martinez; Seiichi Omura; Ikuo Tsunoda
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 4.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

Review 5.  High-dose chemotherapy and multiple sclerosis.

Authors:  Daniel Harrison; Douglas E Gladstone
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

Review 6.  Fingolimod is a potential novel therapy for multiple sclerosis.

Authors:  Orhan Aktas; Patrick Küry; Bernd Kieseier; Hans-Peter Hartung
Journal:  Nat Rev Neurol       Date:  2010-06-15       Impact factor: 42.937

Review 7.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.